Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults-Reference-Cited by-同舟云学术

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults

Published:2018-06-14 Issue:2 Volume:8 Page:223-233
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Maes Andrea¹,DePetrillo Paolo²,Siddiqui Shahid³,Reisner Colin¹³,Dorinsky Paul⁴

Affiliation:

1. Pearl – a member of the AstraZeneca group Morristown NJ USA

2. Pharmaron Baltimore MD USA

3. AstraZeneca Gaithersburg MD USA

4. Pearl – a member of the AstraZeneca group Durham NC USA

Funder

Pearl - a member of the AstraZeneca group

AstraZeneca, Cambridge, UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.585

Reference41 articles.

1. European Respiratory Society.European Lung White Book.2013.http://www.erswhitebook.org/. Accessed December 14 2017.

2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

3. World Health Organization.Chronic obstructive pulmonary disease (COPD) Fact sheet.2017.http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed June 13 2017.

4. Global Initiative for Chronic Obstructive Lung Disease.Global Strategy for the Diagnosis Management and Prevention of COPD.2018.http://www.goldcopd.org. Accessed November 15 2017.

5. A rational approach to single, dual and triple therapy in COPD

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential;Pulmonary Pharmacology & Therapeutics;2023-12

2. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease;Translational Lung Cancer Research;2023-08

3. Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma;Expert Opinion on Drug Metabolism & Toxicology;2023-06-03

4. The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly;Contrast Media & Molecular Imaging;2022-08-17

5. Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease;Tropical Journal of Pharmaceutical Research;2022-06-18